Exactech Goes Private in $625M Deal With TPG Capital Post author:Sam Post published:October 22, 2017 Post category:BioPharma TPG Capital has acquired all the outstanding shares of Exactech common stock for $42 per share. Source: BioSpace You Might Also Like Agile Therapeutics, Inc. Announces A Poster Presentation Of Its SECURE Phase III Study At The Conference March 16, 2017 Prevail Therapeutics Grabs $75 Million to Advance Parkinson’s Disease Programs March 7, 2018 Cidara Touts Positive Phase II Antifungal Data March 18, 2018
Agile Therapeutics, Inc. Announces A Poster Presentation Of Its SECURE Phase III Study At The Conference March 16, 2017